Please try another search
For the nine months ended 30 September 2019, Karessa Pharma Holding AB (publ) revenues was not reported. Net loss decreased 19% to SEK14M. Lower net loss reflects Research and Development Expense decrease of 18% to SEK11.8M (expense), Other Operating Income increase from SEK142K to SEK499K (income), Selling Costs decrease of 16% to SEK1.2M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -SEK1.57 to -SEK1.27.
Period Ending: | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 |
---|---|---|---|---|
Total Revenue | 0 | 0 | 0 | 0 |
Gross Profit | ||||
Operating Income | -4.49 | -4.62 | -4.95 | -14.85 |
Net Income | -4.49 | -4.6 | -4.92 | -14.83 |
Period Ending: | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 |
---|---|---|---|---|
Total Assets | 91.19 | 95.98 | 100.57 | 106.28 |
Total Liabilities | 1.44 | 1.73 | 1.74 | 2.53 |
Total Equity | 89.75 | 94.25 | 98.83 | 103.75 |
Period Ending: | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 |
---|---|---|---|---|
Period Length: | 9 Months | 6 Months | 3 Months | 12 Months |
Cash From Operating Activities | -7.88 | -5.6 | -3.14 | -13.12 |
Cash From Investing Activities | 0 | 0 | 0 | 0.2 |
Cash From Financing Activities | 0.05 | 0.04 | 0.02 | 0.08 |
Net Change in Cash | -7.83 | -5.56 | -3.12 | -12.84 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review